Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies (Q35085359)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies (English)

1 reference

Europe PubMed Central

6 August 2017

postmenopausal osteoporosis

1 reference

based on heuristic

inferred from title

author name string

Ralph C Schimmer

1

1 reference

Europe PubMed Central

6 August 2017

Frieder Bauss

2

1 reference

Europe PubMed Central

6 August 2017

publication date

1 January 2003

1 reference

Europe PubMed Central

6 August 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

6 August 2017

25

1 reference

Europe PubMed Central

6 August 2017

1

1 reference

Europe PubMed Central

6 August 2017

19-34

1 reference

Europe PubMed Central

6 August 2017

The crippling consequences of fractures and their impact on quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The socioeconomic burden of fractures: today and in the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Decline in physical function following hip fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Osteoporosis. Frequency, consequences, and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life related to fear of falling and hip fracture in older women: a time trade off study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New bisphosphonates in the treatment of bone diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Bisphosphonates: from the laboratory to the clinic and back again

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Esophagitis associated with the use of alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Alendronate gastric ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly administration of alendronate: rationale and plan for clinical assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Adverse effects of bisphosphonates. A comparative review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Editorial: Single daily dose of antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring compliance with inhaled medication in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Renal failure associated with intravenous diphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990005-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(03)90005-1

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35085359&oldid=1953846989"